StockWatch
·
SHALBY LTD · QQ2 FY-2027 · THE CALL

9% growth masked by margin compression; Gurgaon bright spot offsets hospital headwinds

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsSHALBYShalby Ltd07 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade C

Hospital EBITDA margin (18.2%) misses 20% target. ROCE (9.4%) below 11-13% guidance. No miss on revenue growth (+9.7% on track).

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Shalby shows genuine progress on Gurgaon scaling and capex discipline (₹10 Cr per half), but near-term margins are compressing (hospital 18.2% vs 19.5%, down from 20% guidance) and PAT fell 24.9% QoQ despite 9.7% YoY revenue growth. ROCE at 9.4% lags 11-13% target. The call mixed confidence on long-term (Gurgaon PBT breakeven Q3/Q4, MedTech now EBITDA positive) with execution headwinds and strategy ambiguity (hospital vs MedTech focus).

₹313.2 Cr

Revenue · +9.7% YoY

₹7.9 Cr

Reported PAT · +8.3% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Hospital business remains core, profitable activity with significant headroom

OVERSTATED

Stand-alone hospital margin 18.2% vs 19.5% YoY; below 20% guidance; occupancy at 52% vs 48%, still below potential

Gurgaon unit delivering strong growth trajectory and approaching breakeven

MET

Gurgaon revenue ~₹30 Cr vs ₹20 Cr (50% YoY growth), EBITDA positive for 2 consecutive quarters, occupancy 55%, ARPOB ₹96k (+18% YoY)

ROCE expansion progressing toward 11-13% industry standard

MISS

Annualized ROCE now 9.4%, below the 11-13% prior guidance target

MedTech targeting double-digit EBITDA margins post-regulatory changes

OVERSTATED

MedTech EBITDA positive for 5 consecutive quarters but consolidated EBITDA only ₹3.6 Cr; no margin percentage disclosed; still building volumes

Margin support expected from operational efficiencies and new supply chain model

Partial

EBITDA margin flat YoY at 14.6% vs 15.9%; hospital margin compressed despite efficiency initiatives cited; benefits deferred to Q4 onwards

Earnings quality

What changed since the last call

Deltas vs. the prior call

Gurgaon unit accelerating

Upgrade

Revenue ~₹30 Cr vs ₹20 Cr (50% YoY); EBITDA positive for 2 consecutive quarters; occupancy 55%; ARPOB ₹96k (+18% YoY) vs prior guidance vague on Gurgaon timeline

Hospital margin pressured

Downgrade

Stand-alone margin 18.2% vs 19.5% YoY (-130 bps), vs prior guidance target of 20%. Cost headwinds cited; no specific recovery timeline

ROCE missed guidance

Downgrade

Annualized ROCE 9.4% vs prior 11-13% target. Capex ROI deferred; prior guidance implied improvement, not stagnation

MedTech status: now EBITDA positive

Upgrade

5th consecutive quarter of positive EBITDA; consolidated Q2 ₹3.6 Cr vs ₹1.6 Cr Q1. Still no path to double-digit margins quantified

The Q&A

Analysts pressed hard on hospital business profitability vs implant subsidiary losses (INR165 Cr over 3 years) and strategic focus. Management defended hospital 'core' status and cited turnaround opportunity in implants, but deflected on specific hospital-only capex allocation and forward profitability milestones.

The exchanges that mattered

Hospital vs MedTech strategy — Moksh Morbia, Prospero Tree

Partial

Hospital business is core, profitable, with 50% revenue upside. Implants are strategic diversification; facility acquired at ₹1,100 Cr, costs halved, positioning as long-term opportunity. New supply chain reducing cost 30-40%.

Implant subsidiary losses — Moksh Morbia, Prospero Tree

Partial

Cost structure was inherited, now optimized. New supply chain and product expansion expected to improve profitability. Management claims 'all fresh capital will be invested in hospitals, 80-90% of new capex.'

NPPPA drug capping impact — Kashish Thakur, Elara Securities

Answered

Notification expected mid-November. Expect 30% margin from MRP. Internal analysis shows limited impact; already modeled in guidance. Majority of surgeries bundled, medicines not sold separately.

Gurgaon profitability timeline — Moksh Moury; Kashish Thakur, Elara Securities

Answered

Unit now EBITDA positive for 2 consecutive quarters at H1 level. Occupancy growing, specialties adding yield. Expecting PBT breakeven by Q3/Q4 FY27. ARPOB ₹96k (+18% YoY).

Capex and tax rate FY27 — Kashish Thakur, Elara Securities

Answered

H1 capex ₹10 Cr, similar in H2. Tax rate fallen to 24% (vs 35% prior year) due to Gurgaon unit losses offset. ETR expected 45-50% with EBITDA improvements; further reduction possible.

FY27 revenue and margin guidance — Kashish Thakur, Elara Securities

Partial

Double-digit growth in topline expected (H1 tracking this). Hospital margin support from new supply chain, efficiency, NPPA benefits, additional specialists. Full-year benefit in Q4; H2 will be stronger than H1 in terms of growth and margins.

MedTech 2-3 year roadmap (EBITDA, debt reduction) — Supraja, Cuz Limited

Dodged

Unable to give numbers due to new supply chain and expansion. Expect benefits to accrue gradually over rest of FY27 and beyond. Debt will reduce with EBITDA positive, cash flow improvement. No specific EBITDA margin or debt target quantified.

Expansion plans (Mumbai, others) — Kashish Thakur, Elara Securities

Partial

Mumbai expansion delayed with trustee approvals pending. Other avenues being evaluated. No update timeline provided. Focus on utilization of existing infrastructure.

FOSO (Franchise of Standalone Orthopedic) strategy — Kashish Thakur, Elara Securities

Answered

Only concentrating on profitable FSOSs. Limited operations to profitable FSOSs. Quality KPI focus, not just financial. Selective approach on new FSOSs.

Guidance

Forward guidance and management's confidence

Double-digit topline growth for FY27 (from H1 reference: +9.8% delivered)

Medium

H1 tracking; H2 expected stronger than H1. No specific FY27 revenue target quantified; implied 10%+ if double-digit claim holds.

Hospital EBITDA margin targeting upward toward 20% for FY27 (prior Q1 guidance)

Low

Current stand-alone margin 18.2% (vs 19.5% YoY); compression 130 bps. No explicit reaffirmation on 20% target this call; only stated benefits from Q4 onwards. Execution risk evident.

MedTech targeting double-digit EBITDA margins post-regulatory changes (6-9 months from Q1 guidance)

Low

Currently EBITDA positive only; no margin percentage disclosed. Supply chain benefits deferred to H2 FY27 and FY28. No specific margin target quantified.

H1 ₹10 Cr capex; similar level expected in H2 (total ~₹20 Cr for FY27)

High

H1 actual delivered; hospital tech investments (robotics, scanners), MedTech supply chain setup, Gurgaon FSI utilization.

Risks the call surfaced

Ranked by how much they should concern a holder

Execution on margin guidance

High

Hospital margin 18.2% vs 20% guidance, down 130 bps YoY. Cost headwinds (staffing, utilities) not yet offset by efficiency gains. Q4 benefits promised but track record of compression in Q2 raises doubt.

ROCE below target

High

Annualized ROCE 9.4% vs prior guidance of 11-13% expansion target. Capex running at ₹10 Cr per half; if ROI on new beds/tech underperforms, ROCE will remain stuck below guidance.

MedTech profitability path

Medium

MedTech acquired in 2021 with ₹165 Cr cumulative loss over 3 years. Now EBITDA positive for 5 consecutive quarters, but no specific margin % disclosed. Management deferred quantified roadmap, citing inability to share numbers.

Hospital occupancy execution

Medium

Stand-alone occupancy 52% (48% prior), +400 bps YoY. Gurgaon at 55%. Management claims 'some hospitals still operating below potential,' implying utilization risk. 50% revenue upside if fully leveraged, but timing uncertain.

Gurgaon unit dependency

Medium

Gurgaon contributed 50% revenue growth (₹30 Cr vs ₹20 Cr), but represents ~10% of hospital revenue. Occupancy at 55% and ARPOB growing, but PBT breakeven by Q3/Q4 is a tight timeline if costs rise.

Debt and capex cycle mismatch

Medium

Net debt ₹458 Cr (gearing 0.45x); capex ₹10 Cr per half (~₹20 Cr annual). If capex ROI lags and occupancy doesn't improve, debt-to-EBITDA could deteriorate. Management claims confidence in debt reduction but specific milestones absent.

NPPPA drug capping regulatory risk

Low

NPPPA capping 180 molecules (oncology focus). Management expects 30% MRP margin; claims limited impact since medicines bundled in surgeries. But if implementation is harsher or affects implant-related pharma, margins could compress.

Management

Score 7/10. Candid on challenges (margin compression, occupancy 'below potential,' cost headwinds). Evasive on MedTech profitability roadmap and long-term strategic focus (hospital vs implants); deferred numbers on both. Clear on capex and tax rate guidance. Mixed track record. Hospital EBITDA margin missed 20% guidance (18.2% current). ROCE below 11-13% guidance at 9.4%. Gurgaon tracking well (50% growth, EBITDA positive). Revenue growth on track (+9.7% YoY, on pace for double-digit FY27). Cost control improving (inventory down 20%, ALOS improved).

What to watch next
  • 1 · Q3/Q4 FY27

    Gurgaon (Shalby International) targeting PBT breakeven; EBITDA benefits flow through

  • 2 · Q4 FY27

    New MedTech supply chain cost reductions fully effective; manufacturing yield improvements realized

  • 3 · H2 FY27

    Additional specialist doctors added across network to drive multi-specialty growth and occupancy utilization

The call mixed confidence on long-term (Gurgaon PBT breakeven Q3/Q4, MedTech now EBITDA positive) with execution headwinds and strategy ambiguity (hospital vs MedTech focus).

Informational and educational content only. Not investment advice.